Early Detection Opportunity Micrima’s Mi Scan technology aims to provide rapid, safe breast tissue analysis and BI-RADS density classification to enable earlier detection and risk assessment, presenting a strong value proposition for clinics seeking proactive imaging workflows and personalized screening programs.

Integrated Risk Scoring Mi Score software combines density data with established breast cancer risk models, offering a compelling selling point to hospital radiology departments and private clinics that want integrated, decision-support tools within their imaging IT ecosystem.

CE Mark and Partnerships The company’s CE-marked radiowave imaging system and ongoing investor activity signal readiness for market adoption; sales outreach can target NHS/private care networks, imaging centers, and potential integration partners seeking certified, innovative breast imaging solutions.

Growth and Funding Signals With substantial funding to date and a focused product roadmap, Micrima is positioned to scale; opportunities exist to collaborate on pilots, clinical studies, and joint go-to-market programs with distributors and regional partners.

Global Awareness Recent press and industry event participation (RSNA, UK launch news) indicate rising visibility; leverage this momentum to secure speaking engagements, pilot agreements, and published outcomes that can accelerate procurement cycles in multiple markets.